AI Insight
This phase 3 randomized controlled trial investigated the combination of 177Lu-PSMA-617 (a radioligand therapy) with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPI) in patients with PSMA-positive metastatic prostate cancer who were treatment-naive or sensitive to androgen pathway modulators. The combination therapy significantly prolonged radiographic progression-free survival compared to standard treatment alone. While adverse events occurred more frequently with the combination therapy, no unexpected safety concerns were identified.
Why it matters
This trial establishes a potential new first-line treatment strategy for patients with metastatic prostate cancer that is still responsive to hormonal therapies. The findings could expand treatment options for this patient population and potentially improve outcomes by combining targeted radioligand therapy with existing standard treatments earlier in the disease course.
Understand the Science
Combining 177Lu-PSMA-617 with ADT plus ARPI prolonged radiographic progression-free survival in patients with PSMA-positive metastatic APMN/S prostate cancer. Although adverse events were more frequent, there were no unexpected safety findings associated with the drug combination. Therefore, combining 177Lu-PSMA-617 with ADT plus ARPI might be a new treatment option in metastatic APMN/S prostate cancer.